Evidence supporting the use of: N-Acetyl Cysteine
For the health condition: Tuberculosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

N-Acetyl Cysteine (NAC) has garnered some scientific attention for its potential role as an adjunctive therapy in tuberculosis (TB) management, but the evidence remains preliminary. NAC is a precursor to glutathione, a major intracellular antioxidant, and it has mucolytic and anti-inflammatory properties. In the context of TB, oxidative stress and lung tissue damage are significant concerns, and boosting antioxidant defenses could theoretically mitigate tissue injury and improve outcomes.

Small-scale in vitro and animal studies have demonstrated that NAC can inhibit Mycobacterium tuberculosis growth, possibly by enhancing macrophage function and reducing oxidative stress. Some clinical studies (mostly pilot studies and small randomized controlled trials) have explored NAC as an adjunct to standard anti-TB therapy. These have suggested potential benefits, such as reduced inflammation, improved lung function, and decreased hepatotoxicity from anti-TB drugs. However, these studies are limited by small sample sizes and methodological weaknesses.

No large-scale, high-quality human trials have definitively established NAC as a standard treatment or adjunct for TB. Major clinical guidelines do not currently recommend NAC for TB management outside research settings. In summary, while there is a scientific rationale and some early evidence supporting the use of NAC in TB, the clinical evidence is limited, and more robust studies are needed to validate its efficacy and safety.

More about N-Acetyl Cysteine
More about Tuberculosis

Products containing N-Acetyl Cysteine

We currently have no products on Vitabase that contain this ingredient.